Health Care & Life Sciences » Biotechnology | Global Blood Therapeutics Inc.

Global Blood Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
534.00
666.00
873.00
1,235.00
1,658.00
4,607
Gross Income
534.00
666.00
873.00
1,235.00
1,658.00
4,607
SG&A Expense
15,129.00
19,845.00
45,520.00
81,892.00
117,587.00
178,135
EBIT
15,663.00
20,511.00
-
83,127.00
119,245.00
182,742
Unusual Expense
2,455.00
297.00
-
-
-
-
Non Operating Income/Expense
-
-
33.00
659.00
334.00
69
Pretax Income
18,116.00
20,807.00
46,360.00
82,468.00
117,024.00
174,193
Consolidated Net Income
18,116.00
20,807.00
46,360.00
82,468.00
117,024.00
174,193
Net Income
18,116.00
20,807.00
46,360.00
82,468.00
117,024.00
174,193
Net Income After Extraordinaries
18,116.00
20,807.00
46,360.00
82,468.00
117,024.00
174,193
Net Income Available to Common
19,851.00
23,772.00
50,540.00
82,468.00
117,024.00
174,193
EPS (Basic)
0.91
1.09
3.95
2.48
2.76
3.41
Basic Shares Outstanding
21,799.50
21,799.50
12,806.70
33,207.40
42,323.70
51,150.70
EPS (Diluted)
0.91
1.09
3.95
2.48
2.76
3.41
Diluted Shares Outstanding
21,799.50
21,799.50
12,806.70
33,207.40
42,323.70
51,150.70
EBITDA
15,129.00
19,845.00
45,520.00
81,892.00
117,587.00
178,135
Non-Operating Interest Income
2.00
1.00
-
-
2,555.00
8,618
Preferred Dividends
1,735.00
2,965.00
4,180.00
-
-
-

About Global Blood Therapeutics

View Profile
Address
171 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.gbt.com
Updated 07/08/2019
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.